This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Genzyme Corporation. Active years: 2022-2025.
Company Filing History:
Years Active: 2022-2025
Title: Linli Wei - Innovator in CSF-1R Inhibitors
Introduction
Linli Wei is a notable inventor based in Waltham, MA, specializing in the development of compounds that serve as inhibitors for the colony stimulating factor-1 receptor (CSF-1R). His innovative work has led to the creation of a patent that holds significant potential in the field of medical research and treatment.
Latest Patents
Linli Wei holds a patent for compounds that are useful as CSF-1R inhibitors. This patent represents a crucial advancement in the understanding and treatment of diseases related to the CSF-1R pathway. The compounds outlined in his patent are designed to inhibit the receptor, which may have therapeutic implications in various medical conditions.
Career Highlights
Linli Wei is currently employed at Genzyme Corporation, a leading biotechnology company known for its focus on developing innovative therapies. His work at Genzyme has allowed him to contribute significantly to the field of biotechnology and pharmaceuticals.
Collaborations
Throughout his career, Linli Wei has collaborated with esteemed colleagues, including John L. Kane, Jr. and Claude Barberis. These collaborations have fostered a productive environment for innovation and research, enhancing the impact of their collective work.
Conclusion
Linli Wei's contributions to the field of CSF-1R inhibitors exemplify the importance of innovation in biotechnology. His patent and work at Genzyme Corporation highlight his role as a key figure in advancing medical research and potential treatments.